Evidence map›Paper›PMID 34111829›Full record

ArticleEuropean journal of medicinal chemistry2021

A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.

Muhamad Mustafa, Amer Ali Abd El-Hafeez, Dalia Abdelhamid, Gajanan D Katkar, Yaser A Mostafa, Pradipta Ghosh, Alaa M Hayallah, Gamal El-Din A Abuo-Rahma

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Harnessing Substituted 4-Chlorothieno[2,3-Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. The Development of FAK Inhibitors: A Five-Year Update.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Muhamad MustafaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.
Amer Ali Abd El-HafeezPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. Electronic address: aam002@health.ucsd.edu.
Dalia AbdelhamidDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Gajanan D KatkarDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Yaser A MostafaPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, 71526, Egypt.
Pradipta GhoshDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA; Department of Medicine, University of California San Diego, La Jolla, CA, USA; Moores Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA; Veterans Affairs Medical Center, La Jolla, CA, USA.
Alaa M HayallahPharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, 71526, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt.
Gamal El-Din A Abuo-RahmaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt. Electronic address: gamal.aborahma@mu.edu.eg.
Deraya UniversityAssiut University · EGCairo University · EGMinia University · EGSphinx University · EGUniversity of California San Diego · USVeterans Health Administration · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Spatial Regulation of RGS and G Protein SignalingR01CA100768 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2003 to 2019
$7.4M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Modulation of G proteins by Growth FactorsR01CA160911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2013 to 2017
$1.8M
NCI NIH HHS R01 CA100768NCI NIH HHS R01 CA160911NCI NIH HHS R01 CA238042NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

Novel 5-pyridinyl-1,2,4-triazoles were designed as dual inhibitors of histone deacetylase 2 (HDAC2) and focal adhesion kinase (FAK). Compounds 5d, 6a, 7c, and 11c were determined as potential inhibitors of both HDAC2 (IC

Indexed as

Antineoplastic AgentsApoptosisBenzamidesCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFocal Adhesion Kinase 1Histone Deacetylase 2Histone Deacetylase InhibitorsHumansHydroxamic AcidsMolecular StructureProtein Kinase InhibitorsStructure-Activity RelationshipTriazolesTumor Cells, CulturedAntineoplastic AgentsBenzamidesFocal Adhesion Kinase 1HDAC2 protein, humanHistone Deacetylase 2Histone Deacetylase InhibitorsHydroxamic AcidsProtein Kinase InhibitorsPTK2 protein, humanTriazoles1,2,4-TriazolesAnticancerFAKHDAC2Molecular docking

Identifiers

PMID34111829
PMCPMC8818328
OpenAlexW3166075453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.